Clinical Trial Detail

NCT ID NCT03207256
Title Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.

non-Hodgkin lymphoma

chronic lymphocytic leukemia


Ublituximab + Umbralisib


Age Groups: child senior adult

No variant requirements are available.